<DOC>
	<DOCNO>NCT00004144</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness bryostatin 1 plus gemcitabine treating patient advance cancer respond previous treatment .</brief_summary>
	<brief_title>Bryostatin 1 Plus Gemcitabine Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose gemcitabine give concurrently bryostatin 1 patient advanced refractory cancer . - Access pattern toxicity drug regimen patient population . - Determine objective response rate , duration response , overall survival patient treat drug regimen . - Determine influence bryostatin 1 pharmacokinetics gemcitabine . OUTLINE : This dose escalation study . Patients receive gemcitabine IV 30 minute , immediately follow bryostatin 1 IV 24 hour , weekly 3 week ( day 1 , 8 , 15 ) . Treatment repeat every 28 day absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos gemcitabine bryostatin 1 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxic effect . PROJECTED ACCRUAL : Approximately 2-3 patient per month accrue study .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven advanced cancer ( except hematological cancer ) standard therapy fail standard therapy Measurable evaluable disease Clinically control brain metastasis allow PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : At least 3 month Hematopoietic : Hemoglobin least 8.0 g/dL Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) ( elevate bilirubin due Gilbert 's syndrome allow direct bilirubin normal ) AST le 2.5 time ULN Renal : Creatinine normal Cardiovascular : No active cardiac disease Other : Not pregnant nursing Fertile patient must use effective contraception No concurrent bacterial infection require antibiotic No serious concurrent medical condition PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : At least 3 week since systemic cytotoxic chemotherapy ( include gemcitabine ) recover No concurrent chemotherapy Endocrine therapy : Prior hormonal therapy allow No concurrent hormonal therapy ( exclude contraceptive , appetite stimulant , replacement steroid ) Radiotherapy : At least 3 week since radiotherapy large area active bone marrow recover No concurrent radiotherapy Surgery : Recovered prior major surgery Other : No concurrent antiviral nucleoside At least 1 month since prior investigational agent No concurrent experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>